Phase 1 Study of Revumenib in Combination With Intensive Chemotherapy (IC) in Patients (Pts) With Newly Diagnosed (ND) Acute Myeloid Leukemia (AML) Harboring Genetic Alterations in KMT2A, NPM1, or NUP98: SNDX-5613-0708

Poster Presentation | Dec 6, 2025

Author

Aldoss I, et al.

Congress

American Society of Hematology Annual Meeting 2025

Orlando, Florida | Dec 6 – 9, 2025